HighVista Strategies LLC Purchases New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

HighVista Strategies LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 19,808 shares of the company's stock, valued at approximately $542,000. HighVista Strategies LLC owned approximately 0.07% of Dianthus Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC increased its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. Fred Alger Management LLC increased its stake in Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock valued at $264,000 after acquiring an additional 3,316 shares during the last quarter. SG Americas Securities LLC bought a new position in Dianthus Therapeutics in the second quarter valued at approximately $112,000. MetLife Investment Management LLC increased its stake in Dianthus Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company's stock valued at $382,000 after acquiring an additional 7,854 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after acquiring an additional 8,473 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on DNTH. Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, November 11th. Raymond James boosted their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, Wedbush cut their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a report on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH traded down $0.89 during trading on Wednesday, hitting $24.68. 157,695 shares of the company traded hands, compared to its average volume of 206,979. The business's fifty day moving average is $26.60 and its 200 day moving average is $26.53. Dianthus Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The firm has a market capitalization of $730.45 million, a price-to-earnings ratio of -9.87 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.